Fights market consolidation. The government can negotiate a much lower rate on what to pay providers and pharmaceuticals, compared to what is paid today.

Attempts at such influence have already been successfully directed at Medicare, which is specifically prohibited from using its market power to negotiate drug prices. The United States is virtually the only country in the world where this is the case; every other national government negotiates prices with the drug companies. The result is that Amer

... See more

• The US is the only OECD country without some form of universal health coverage, resulting in the US spending twice as much (per capita) than other OECD countries.


• Despite this higher spending, most data shows health outcomes in the U.S. to be worse than other OECD countries, even after adjusting for nuances like above-average obesity.


• A 2020 study by

... See more

There is an obvious risk of regulatory capture; powerful companies or industries may exert influence that bends government policy in their favor. Attempts at such influence have already been successfully directed at Medicare, which is specifically prohibited from using its market power to negotiate drug prices. The United States is virtually the on

... See more

Lack of competition and systemic inefficiencies in healthcare have led to higher costs. Of all the proposals on the table, a single-payer system (“Medicare for all”) would most completely address these issues, but it may politically be unviable and there will inevitably be a rocky transition period.